Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News C4 Therapeutics Inc CCCC

Healthcare Biotechnology
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on advancing targeted protein degradation science to create a new generation of small-molecule medicines that transform patients’ lives. By leveraging its proprietary Target ORiented ProtEin Degrader Optimizer (TORPEDO) platform, to design and optimize small molecule protein degraders that are active against... see more

Recent & Breaking News (NDAQ:CCCC)

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

GlobeNewswire December 8, 2024

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

GlobeNewswire November 20, 2024

C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial

GlobeNewswire November 6, 2024

C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma at the American Society of Hematology (ASH) Annual Meeting

GlobeNewswire November 5, 2024

C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire October 31, 2024

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 28, 2024

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

GlobeNewswire October 15, 2024

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

GlobeNewswire October 9, 2024

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 30, 2024

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

GlobeNewswire September 13, 2024

C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen

GlobeNewswire September 10, 2024

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

GlobeNewswire September 8, 2024

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

GlobeNewswire September 3, 2024

C4 Therapeutics to Participate in Upcoming September Investor Conferences

GlobeNewswire August 29, 2024

C4 Therapeutics Announces European Society for Medical Oncology (ESMO) Changed the Previously Accepted CFT1946 Preliminary Phase 1 Abstract to a Proffered Paper Presentation

GlobeNewswire August 14, 2024

C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire August 1, 2024

C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024

GlobeNewswire July 16, 2024

C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day

GlobeNewswire July 8, 2024

C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors

GlobeNewswire June 10, 2024

C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire May 8, 2024